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A.1 Background information 
 
15.6 million people worldwide are affected by acute rheumatic fever and subsequent 
rheumatic heart disease according to World Health Organisation (WHO) estimates. The 
tonsillo-pharyngeal infection, caused by group A streptococcal infection, results in an 
inflammatory process which affects many organ systems, of which fibrotic changes to 
the heart valves leads to the most incapacitating clinical consequences. It is further 
estimated that 200 000 people die annually of rheumatic heart disease, affecting mostly 
young individuals of the developing world (1,2,3). Rheumatic heart disease remains the 
leading cause of valvular heart surgery in the developing world. 
 
In non-rheumatic pathological processes, like degenerative mitral valve disease, mitral 
valve repair is known to be superior to mitral valve replacement in terms of operative 
mortality, functional outcomes and long-term survival (4,5). Furthermore, mitral valve 
repair excludes the possible complications associated with life-long anticoagulation as 
well as the risk of thrombo-embolism seen with mitral valve replacement (6,7). Mitral 
valve repair is clearly the procedure of choice in non-rheumatic mitral valve disease. 
 
However, the appropriateness of valve repair for patients with rheumatic heart disease, 
even when repair appears to be technically feasible, remains controversial (8,9,10). 
Questions regarding the ongoing fibrotic process of cardiac valves in rheumatic 
pathology and the effect thereof on the repaired valve have been asked. At Groote 
Schuur Hospital, it has been our approach in rheumatic mitral valves to repair the valve 
rather than replace it, whenever the anatomical substrate of the valve appears to be 
favorable.  
 
In view of the above, we propose to review our 10 year, single institution experience 
with repair and replacement of rheumatic mitral valves. This serves to determine the 
advisability of our strategy and the appropriateness of mitral valve repair whenever 

















To answer the question of whether the paradigm remains valid that in a developing 
country,  the benefit of not requiring the insertion of a prosthetic heart valve truly 
outweighs the disadvantages of repeat surgery in the presence of a chronically 




• To retrospectively analyse all cases of single mitral valve repair and single mitral 
valve replacements performed for rheumatic heart disease at Groote Schuur 
Hospital during the period from 1 January 2000 till 31 December 2010 with the 
aim of a propensity-matched outcome comparison, specifically emphasising the 
following aspects: 
o Patient related 
o Pathology related 
o Surgery related 
o Early clinical outcome with emphasis on early mortality and surgical 
related morbidity 
o Late clinical outcome with emphasis on late mortality and late valve 
related morbidity 
(see materials and methods section for further details of the above aspects 
which will be investigated) 
 
A.3. Institutional approval 
 
This proposal was submitted for ethics approval to the University of Cape Town 















The study population is from Groote Schuur Hospital, which serves as a referral centre 





The surgical database of the Chris Barnard Division of Cardiothoracic Surgery will be 
scrutinized for: 
Inclusion criteria: 
• All cases of rheumatic heart disease during the last decade where a single mitral 
valve repair or replacement was performed as a first open cardiac surgical 
procedure. 
• Cases which had concomitant tricupsid valve annuloplasty for functional 
tricuspid regurgitation will be included. 
• Cases where concomitant Cox-maze ablation therapy of atria was performed for 
treatment of pre-operative atrial fibrillation will be included 
• All Patients above 13 years of age will be included  
Exclusion criteria: 
• Previous open cardiac surgery requiring cardiopulmonary bypass 
• Any concomitant cardiac surgery procedures not related to mitral valve disease, 
like aortic valve replacement or coronary artery bypass grafting 
• Mitral valve disease secondary to other pathological processes than rheumatic 
heart disease  















The medical and surgical records of all the patients identified, will be retrospectively 
reviewed. A standardized data collection sheet (Annexure B) will be used to retrieve 
relevant information including: 
 
1. Patient related: age at surgery, sex, race, contact telephone numbers, 
geographical area where patient stay, educational status of patient and type of 
housing (formal or informal) 
2. Specific co-morbidities for surgery: hypertension, dyslipidemia, renal 
dysfunction, diabetes or other co-morbid factors 
3. Classification of functional mitral valve pathology as pure mitral stenosis, pure 
mitral regurgitation or mixed mitral valve disease (both stenotic and regurgitant) 
4. Presence of tricuspid regurgitation and if present graded as trivial, mild, 
moderate or severe 
5. Specification of procedure performed: mitral valve repair or replacement, Cox-
maze procedure, tricuspid annuloplasty 
6. Functional status prior to surgery as graded by New York Heart Association 
(NYHA) grades I to IV and a follow up of the functional status immediately post 
surgery as well as at later follow up 
7. Intra-operative details: Duration of cardiopulmonary bypass and aortic cross 
clamp, type of valve inserted if mitral valve replacement was performed, size of 
valve inserted of mitral valve replacement was performed, the reason for 
selecting a bioprosthesis if mitral valve replacement with bioprosthesis was 
performed, specific surgical repair methods when mitral valve was repaired 
8. Histological evidence of valve pathology where specimens were obtained 
9. The presence of pre-operative atrial fibrillation, post operative atrial fibrillation 
and whether a post operative permanent pacemaker needed to be inserted 
10. Anticoagulation monitoring: whether the patient was previously placed on 
Warfarin and what the pre-operative International Normalized Ratio  (INR) was. 
Number of annual INR checks performed by patient. Which INR clinic was used 












profile and control over the last 12 months as well as the last therapeutic INR 
value.  
11. Early clinical outcome (in hospital outcome during same admission as for this 
surgical procedure) will be reviewed with specific emphasis on: 
o status of repaired mitral valves as determined by intra-operative trans-
oesophageal echocardiography  
o early mortality (during same hospital admission as for this surgical 
procedure) 
o early morbidity with specific emphasis on re-operation for bleeding, 
cerebrovascular events, requirements for permanent pacemaker insertion, 
requirements for renal dialysis and development of deep sternal sepsis 
12. Late clinical outcome (outcome after discharge from hospital for this surgical 
procedure up to latest point of contact at recent follow-up) will be reviewed with 
specific emphasis on: 
o Late mortality with specific emphasis on valve related mortality and all 
cause mortality 
o Late morbidity with specific emphasis on morbidity associated with anti-
coagulation, infective endocarditis, prosthesis failure, paravalvular leaks, 
the need for valve related redo surgery, cerebrovascular events and 
thromboembolism. 
o The presence of post operative atrial fibrillation as part of late follow up 
will specifically be mentioned and this will be referenced to the presence 
of pre-operative atrial fibrillation and whether a Cox-maze procedure was 
performed as anti-arythmia surgery 
13. A telephonic follow up of all the patients will be performed with specific 
emphasis on: 
o Is the patient still alive? (especially if lost to follow-up at clinic 
attendance) 













o Has the patient had any re-operations since the primary valve related 
surgical procedure at any other institution, which we might not be aware 
of? 
o Is the patient taking his/her Warfarin, what was the last INR value and 
which local clinic or hospital is used for INR monitoring? 
14.  Demographics and population migration patterns will be noted at follow-up with 
specific emphasis on: 
o How stable is the domicile of our patients population with relation to 
post-operative access to anti-coagulation and continuity of clinical 
follow-up? 
o Does patients migrate as much as generally perceived between Western 
Cape and other provinces after surgery? 
o Is there a significant percentage of our patients who travel from other 
African countries to the Western Cape for heart surgery? 
 
None of the investigators, supervisors or co-workers involved in this study have any 
conflict of interest to declare. 
 
The patient’s anonymity will be protected by only using the folder numbers and initials 
in the study to indentify the subjects during the data collection phase of the study. 
Patient Jane Smith, folder number 81053623, will be identified in the study as JS 
81053623 and under no circumstances will personal details of the patient be included or 
distributed during the study. No identification of individuals will be done under any 
circumstances during the data review, statistical analysis or during possible future 
publication phases of this study. 
 
A simple oral consent procedure will be followed during telephonic follow up contact 
with patients. It will be conducted in the following way: 
• I am Dr Agneta Geldenhuys, who is following up patients who had surgery for 












• This follow-up is for the purposes of a research project where we are trying to 
establish how our patients is doing who had mitral valve surgery done during the 
last 10 years at Groote Schuur Hospital. 
• Our records show that you had such an operation during this time. 
• Are you willing to discuss your health with me? (you are under no obligation to 
this discussion). 
The understanding that the ongoing ethical conduct of the study remains the 





Guidelines of the Society of Thoracic Surgeons for reporting mortality and morbidity 
after cardiac valve interventions will be used for the analysis and reporting of 
postoperative complications (11). All continuous numerical data will be expressed as 
means ± standard deviation and all actuarial estimates as percentage ± standard error. 
Inferential statistical analysis will be performed using the JMP® statistical software 
package (version 6.0.3, Cary; NC). Propensity score analysis using multiple logistic 
regression independent of outcome variables, will be performed against the pre-
determined covariates of age, sex, body mass index, New York Heart Association 
classification, presence of pre-operative atrial fibrillation and left ventricular end systolic 
dimension. Actuarial curves will be based on Kaplan-Meier analysis with comparison 
between groups performed using the log-rank test. A p-value of <0.05 will be considered 
to be statistically significant. 
 
A.5 Research plan 
 
The project will be conducted over 7 months. The first 5 months will be dedicated to 
data collection of all relevant information. Once all data have been collected, data 












conclude over the next month. The last month will be dedicated to the specific write-up 
of the results and conclusions. Dr A Geldenhuys will be responsible for the conduct of 
the whole research plan, ethical conduct, data collection, data analysis and conclusions. 
She will be assisted by Dr J Koshy in the data collection and analysis and by Juliana 
Mtwale, elective research student, in data handling by creating a computerized database 
for this study. Statistical analysis of the data will be done with the help of Dr Paul 
Human and data analysis will be further reviewed with the help of the supervisors, 
Professors Peter Zilla and Johan Brink. All of the above individuals are members of the 
Christiaan Barnard Division of Cardiothoracic Surgery at Groote Schuur Hospital and  
University of Cape Town. 
 
A.6 OPERATIONAL BUDGET 
 
Administrative and telephonic costs comprises the bulk of the budget: 
• Stationery and printing:  R2000 






The Christiaan Barnard Division of Cardiothoracic Surgery, subject to ethics approval,  
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The objectives of this literature review were to obtain the following background 
information: 
 
• The burden of rheumatic heart disease  
• Appropriateness of different surgical therapies (repair and replacement) for 
rheumatic heart disease versus degenerative heart disease 
• Difference between surgical treatment of rheumatic heart disease in children and 
adults 
• Difference between therapeutic options in developing countries versus the 
developed world 
• Previous studies in South Africa with different follow-up means from a previous 
era 
 
B.2 Search strategy 
 
The literature search was initiated using the Pubmed Central digital archive. Further 
appropriate papers were identified by searching reference lists. Fourteen relevant 
research papers were identified. An author-year referencing method was used. 
 
B.3 Quality criteria 
 
The keywords used for the Pubmed search included rheumatic heart disease and each of 
the following: South Africa, mitral valve disease, mitral valve repair, mitral valve 
replacement, and surgery for rheumatic heart disease. Studies involving mitral valve 
surgery for rheumatic heart disease were selected. Particular attention was given to 













B.4 Summary of the literature 
Almost 16 million people in the world are affected by rheumatic heart disease (1). The 
African continent with less developed countries carries the majority of the burden of this 
disease with the highest worldwide prevalence in sub-Saharan Africa (5.7 per 1000 
school children) (2). Rheumatic heart disease most commonly affects the mitral valve 
and this is the leading cause of valvular heart surgery in the developing world (3).  
 
In degenerative valvular disease (which predominates first world valvular pathology), 
mitral valve repair is the procedure of choice. The repair of these valves has low 
operative morbidity and mortality with superior functional outcome, late survival, 
freedom from re-operation and freedom from thrombo-embolic disease. The avoidance 
of complications associated with life-long anticoagulation in mechanical valve 
replacement serves as a further major advantage of valve repair (4,5,6). 
 
On the other hand, the repair of rheumatic mitral valve disease remains controversial 
especially in view of the associated chronic, ongoing fibrotic process. Disease 
progression in the long term may necessitate mitral valve replacement making repair 
surgery redundant despite its advantages (7,8,9).  
 
Evidence for surgical treatment differs depending on the age of the patient. In children 
with rheumatic heart disease, mitral valve repair is clearly indicated above replacement 
whenever the anatomic substrate permits it in view of a growing heart, accelerated 
degeneration of bioprostheses, and the possibility of orphanage through mass epidemics 
like Human Immunodeficiency Viral (HIV) infections. Antunes et al followed-up 241 
rheumatic mitral valve patients in South Africa in the 1980s; almost half were children 
below 15 years of age (3). With pure or predominant regurgitation in three quarters of 
these patients and a mean follow-up period of 2.6 years, he unequivocally advised repair 
over replacement. In the 1990s, Kumar et al confirmed this conclusion in a paediatric 













In adults the therapeutic dilemma of the superiority of repair over replacement in 
rheumatic mitral valve disease, forms the basis of an ongoing debate. From the 
developed world, Carpentier et al reported in 2001 on a long term (12 year) follow up of 
reconstructive valve surgery in rheumatic mitral valve insufficiency in France, showing 
a re-operation rate of only 2% per patient year with minimal risk of thrombo-embolic 
events and therefore clearly advocates for repair above replacement. (11) David et al 
echo this by showing improved late cardiac survival (independent of pre-operative 
characteristics) in rheumatic mitral valve repair above replacement in Toronto in 2001. 
(12)  
 
Fewer studies are available from developing countries where unique problems exist like 
patient educated adherence to anti-coagulation therapy and infra-structural challenges to 
adhere to treatment and follow-up. Yankah et al followed up patients with endemic 
rheumatic heart disease and a migrant background post mitral valve repair in Germany, 
stating that these valves may be repairable but subsequently fail (13). The only data 
available from South Africa is from the work of Antunes et al in the 1980s in 
Johannesburg. As stated earlier, his patient population was young (mean age 21.5 years 
and 44.4% being below 15 years of age) with a 91% complete follow-up – a remarkable 
effort in a developing country with its limitations in retrospective follow-up of a migrant 
population with limited access to health care. With pure or predominant regurgitation in 
three quarters of these patients, he unequivocally advocated repair above replacement 
(3).  
 
Sliwa et al confirmed in 2010 from The Heart of Soweto Study, Johannesburg, South 
Africa, that rheumatic patients become symptomatic for surgery later in life with a mean 

















B.5 Identification of need for further research 
 
The main possible disadvantages of disease progression on possible re-operation in 
rheumatic mitral valve repair need to be clearly reviewed against the dangers of a 
prosthetic valve in a developing country with difficult access to medical care. The 
current age shift of indigent rheumatic patients presenting for surgery may request a 
change in appropriate surgical therapy.  It is important to identify treatment optimal for 
our local patient population with specific needs in difficult access to medical care 
(especially in rural areas), low average income and still generally inadequate access to 
proper patient education. The only study available in the South African context dates 
from more than 3 decades ago in Gauteng (3). No recent studies are available with no 
previous data from the Western Cape. Sub-Saharan Africa has the highest incidence of 
rheumatic heart disease (2) with an age shift towards later presentation for surgery in the 
modern era (16). It is therfor critical that the choice of appropriate therapy for rheumatic 
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Background and aim of the study: In developing countries rheumatic heart disease is 
the predominant indication for cardiac surgery. As the disease tends to progress, re-
operation rates for mitral valve repairs are high. Against this background we assessed 
predictors of failure and compared the overall performance of repairs with replacements 
in a 10-year cohort of rheumatic single mitral valve (MV) procedures. 
Methods: Between 2000 and 2010, 560 consecutive adult (>13yrs) patients had a 
primary, single mitral valve procedure. Of the 215 primary MV repairs 69 were 
rheumatic (32%) as opposed to 281 out of 345 in primary MV replacements (81%). Of 
the 281 single MV replacements for rheumatic disease an equal number of 69 were 
propensity-matched with the repair group. Based on propensity score analysis, Kaplan-
Meier actuarial analysis with log-rank testing was used to evaluate survival and 
morbidity.  
Results: Follow-up was 100% complete (n=138) and ranged from 0.6 months to 132.5 
months [Mean 53.32±36.48].  Of all rheumatic single MV procedures, 19.7% were 
repaired. Actuarial freedom from valve-related mortality was 95.6±3.1% and 91.7±3.6% 
at 5 years and 95.6±3.1% and 80.2±11.2% at 10 yrs for repairs and replacements, 
respectively (NS). Actuarial freedom from all valve related events (deaths, re-operations 
and morbidity) was 79.8±5.8%and 85.6±4.5% at 5 years and 69.8±8.4%and 69.2±10.7% 
at 10 years (NS). Actuarial freedom from all valve related events was 57.1±11.1% and 
95.5±3.1% at 5 years (p=0.0008) and 41.6±12.4% and 95.5±3.1% at 10 years (p<0.001) 
for those mitral valve repairs with and without commissural fusion, respectively 
(p=0.0002 overall).  
Conclusions: The long-term results for mitral valve replacement in an indigent, 
rheumatic heart disease population of a developing country are distinctly better than 
generally perceived. Notwithstanding, mitral valve repair has a superior long-term 














Mitral valve repair has become the undisputed procedure of choice for degenerative 
mitral incompetence, the predominant cause of mitral disease in the industrialized world. 
Yet, there remains uncertainty whether repair should also be the preferential therapy in 
the predominantly rheumatic patients of developing countries (1). In a disease that is 
chronic and progressive, there is concern that repair would result in re-operation rates 
that would put additional strain on the limited resources of a developing country. 
Moreover, re-operation may potentially not even be available due to limited access to 
cardiac surgery. These concerns are opposed by the complications of life-long 
anticoagulation for mechanical prostheses in an environment where “non-compliance” is 
often due to logistical impediments such as access to uninterrupted supply of anti-
coagulation medication and regular INR controls. In an uneducated population, patient 
ignorance of the necessity for anti-coagulation is also a factor. Similarly, absence from 
work or even the fare for transport to the nearest clinic, may be another insurmountable 
obstacle to anticoagulation.  
In children and young adults, a growing heart, accelerated degeneration of bioprosthesis, 
and the possibility of orphanage through mass epidemics like Human Immunodeficiency 
Viral (HIV) infections clearly favour mitral valve repair over replacement. In the 1980s 
Antunes et al followed-up 241 rheumatic mitral valve patients in South Africa; almost 
half were children below 15 years of age (2). With pure or predominant regurgitation in 
three quarters of these patients and a mean follow-up period of 2.6 years, he 
unequivocally advised repair over replacement. In the 1990s, Kumar et al confirmed this 
conclusion in a paediatric series from New Delhi (3). 
In adult patients, however, the situation is less clear-cut. Yankah et al concurred with 
others that ‘in regions with endemic rheumatic fever ‘mixed mitral valve lesions may be 
repairable but subsequently fail’(1),(2-5). This conclusion was based on the ability to 
follow-up rheumatic patients with migrant backgrounds in an industrialized country and 
may not stand up to a holistic analysis of circumstances in a developing country. Yet, to 
be able to weigh the overall dangers of disease progression and re-operation, against the 












would be needed. Except for isolated heroic follow-up efforts such as Antunes’(2), 
however, little information is available on post-operative adult rheumatic patients in 
developing or threshold countries. In the absence of such follow-up studies, centres that 
provide cardiac surgery often relied on common sense rather than facts for therapeutic 
decisions. In contrast to the 1980s when Antunes reported his results, the rapid and 
broad penetration of mobile phones into developing countries has dramatically changed 
the follow-up conditions. Together with advancements in information technology such 
as centralized population registries and nation-wide database-linked laboratory-services, 
patient follow-up studies in developing countries have higher chances of success today 
than two decades ago.  
Utilizing these contemporary means of communication we attempted to clarify, in a 
retrospective cohort study, whether the avoidance of anti-coagulation outweighs the 
disadvantages of disease progression in rheumatic patients undergoing mitral valve 












PATIENTS AND METHODS 
Patients 
Between January 2000 and December 2010, 560 consecutive, single, first time mitral 
valve procedures with or without tricuspid annuloplasty and modified Maze procedures 
were performed in adult patients (>13years) at Groote Schuur Hospital, University of 
Cape Town, South Africa.  215 MV repairs (69 for rheumatic heart disease, 53 for 
ischemic heart disease, 45 for degenerative disorders, 23 for adult congenital heart 
disease, 21 for infective endocarditis and 4 for trauma) and 345 MV replacements (281 
rheumatic; 46 infective and 18 degenerative) were performed.  Of the total of 350 
patients who had single mitral valve procedures for rheumatic heart disease, 69 (19.7%; 
54 women; 15 men) had MV repair performed by two experienced surgeons. A further 
12 had an attempted repair, which failed and had immediate replacement. 
281 single MV replacements were performed for rheumatic heart disease and from this 
group an equal number of 69 (58 women; 11 men) were propensity-matched with the 
repair group. The clinical data of these patients are shown in table I.  
All study patients had a strong history of rheumatic fever; 99.3% gave a domiciliary 
address within the Western Cape Province of South Africa at the time of surgery and 
6.5% were HIV positive. 
Preoperatively, trans-thoracic echocardiography was performed to assess the mitral 
valve features as listed in table II.  Patients were excluded from attempted repair if the 
leaflets were too extensively diseased and immobile. The degree of regurgitation was 
based on Doppler echocardiography criteria (6, 7).  Intra-operative trans-oesophageal 
echo was performed in all repair patients.  
 
Surgery 
A conventional median sternotomy approach with ascending aorta and bi-caval 
cannulation, moderate hypothermia (32ºCelsius), antegrade cardioplegia and a left 
atriotomy was used in all patients. In mitral valve replacements, the posterior leaflet 
could be preserved in 37.7%. In the replacement group 63 patients (91.3%) received a 
bi-leaflet prosthesis [On-X: 25; St Jude: 24; Edwards Mira: 14]. If socioeconomic 












planned, tissue valves were used [Medtronic Mosaic: 4; Carpentier Edwards Pericardial: 
2].  Details of MV repair techniques are summarized in table II. Patients were 
commenced on Warfarin therapy on post-operative day 1 and monitored by regular INR 
testing.  Subcutaneous Heparin was used as an adjunct anti-coagulant until a stable 
therapeutic INR was obtained within the range of 2.0-3.5. 
 
Data Collection and Postoperative Follow-up 
Approval was obtained from the institutional ethics review board of the University of 
Cape Town to perform this retrospective, propensity-matched cohort study including 
permission to access national databases.  
Post-operatively, patients from the metropolitan area were reviewed at the cardiac clinic 
at Groote Schuur Hospital and patients from outside the metropole were reviewed at 
regional hospitals. Routine visits were scheduled for 6 weeks and 6 months post-
operatively, and thereafter, annually. All patients on anti-coagulation (those with 
mechanical valve prostheses and those in atrial fibrillation) were scheduled for monthly 
INR testing at their local health-care facility. 
Active data collection for this study was undertaken between January and June 2011. 
Seventy-one percent of patients were contactable telephonically (land telephone lines: 
28.2% and/or mobile phones: 42.8%).  8.7% of patients were traced through the 
metropolitan hospital-link database (Clinicom) to determine their point of care in the 
healthcare system. In 14.5% of cases, patients were found via the National Health 
Laboratory Service’s database that was consulted for the patient’s INR testing. Their 
functional status were then verified by their local health care providers or a community 
health care worker that visited the patient’s physical address. A further 5% of patients 
were uncontactable but returned for a routine appointment to the cardiac clinic at Groote 
Schuur Hospital during this January to June period.  Less than 1% of patients were 
traced by means of the National Department of Interior’s population registry.  
Follow-up was 100% complete (n=138) and ranged from 0.6 months to 132.5 months 
[Mean 53.32±36.48 (Repairs: 54.36±35.76, Replacements 52.68± 36.0)]. Total follow-














Guidelines of the Society of Thoracic Surgeons for reporting mortality and morbidity 
after cardiac valve interventions were used for the analysis and reporting of 
postoperative complications(8). All continuous numerical data were expressed as means 
± standard deviation and all actuarial estimates as percentage ± standard error. 
Inferential statistical analysis was performed using the JMP® statistical software 
package (version 6.0.3, Cary; NC). Propensity score analysis using multiple logistic 
regression independent of outcome variables, was performed against the pre-determined 
covariates of age, sex, body mass index, New York Heart Association classification, 
presence of pre-operative atrial fibrillation and left ventricular end systolic dimension. 
Nearest-neighbour matching (non-caliper) of repair group and replacement patient 
population propensity scores was performed using an in-house iterative algorithm using 
Filemaker Pro® (version 6.0; Santa Clara; CA). Actuarial curves were based on Kaplan-
Meier analysis with comparison between groups performed using the log-rank test. 
Comparison at discrete time points was by Fisher’s Exact test. Post-hoc comparison of 
normally distributed continuous numerical data, based on Shapiro-Wilk testing, was 
performed using the unpaired Student’s T-test or, alternatively the non-parametric 
Wilcoxon test. Comparison of categorical data was performed using Fisher’s exact or 















Early Clinical Outcome 
Post-operative echocardiography of all mitral repair patients indicated no regurgitation 
in 23 patients (33.3%); trivial regurgitation in 35 patients (50.7%) and mild regurgitation 
in 11 (15.9%). There was no echocardiographic evidence of significant mitral stenosis. 
There was no hospital mortality in the repair group versus 1 death (1.5%) in the 
replacement group. Re-exploration for bleeding was necessary in 2 patients in both the 
repair and replacement groups.   No post-operative cerebro-vascular event occurred in 
the repair group versus one in the replacement group. Permanent pacemaker insertion for 
conduction disturbances was necessary in 3 patients in the repair group and 2 in the 
replacement group. No patient required dialysis for acute renal failure or developed deep 
sternal sepsis.  
 
Late Clinical Outcome 
Late Mortality: There were 6 late deaths (8.7%) in the repair group after a median period 
of 36.9 months (range 12-132) and 8 (11.6%) in the replacement group after median 
19.9 months (range 6-113).   The causes of death are listed in table III. 
In the repair group, 3 deaths were valve related: one patient died of a stroke 16 months 
after surgery; one died of a sudden cardiac arrest 55 months following mitral valve 
repair and 11 months after redo mitral valve replacement; and one of congestive heart 
failure with rapid atrial fibrillation with a well-functioning repaired valve after 12 
months.  Two died of cancer, and one of a community acquired pneumonia.  
In the replacement group, 5 of the 8 deaths were valve related: two due to clotted valves 
(both after 14 months); one haemorrhagic stroke (after 120 months); one untreated 
paravalvular leak after 6 months  (probable prosthetic endocarditis); and one ‘sudden 
cardiac arrest’ (after 38 months). Two died of HIV related infections and one was 
murdered.  
Actuarial freedom from all-cause mortality was 90.5±4.1% and 90.2±3.8% at 5 years 
and 90.5±4.1% and 74.0±11.4% at 10 years for the repairs and replacements 












95.6±3.1% and 91.7±3.6% at 5 years and 95.6±3.1% and 80.2±11.2% at 10 years for the 
repairs and replacements respectively. (NS) (Figure 1b). 
Re-operations:   11 patients (8.0%) required reoperation. In the repair group 10 (14.5%) 
required a valve replacement for progressive valve deterioration (3.1 events/100 patient 
years; median period 43.8 months; range 0.9-127.4 months); 4 required replacement 
within the first year (2 for pure regurgitation; 2 for mixed mitral disease) and 6 had a late 
re-operation (5 for mixed mitral valve disease and 1 for regurgitation.)  
In the replacement group, one patient required reoperation within two months for valve 
thrombosis (0.3 events/100 patient years) (Table IV).  
Freedom from re-operation was 82.2±5.8% and 98.5±1.5% at 5 years and 76.3±7.8% 
and 98.5±1.5% at 10 years for repairs and replacements, respectively (p=0.007)(Figure 
2a). 
Within the repair group, several parameters were analyzed to determine factors 
associated with failure of repair. The most striking determinant for the latter was the 
presence of commissural fusion at the initial intraoperative assesment. Sub-analysis of 
the repair group regarding those with and without commissural fusion, (“Fused” and 
“Non-fused” groups respectively), demonstrated an actuarial freedom from re-operation 
of 62.3±11.8% and 95.5±3.1% at 5 years and 53.4±13.0% and 95.5±3.1% at 10 years for 
the two groups, respectively (p=0.004)(Figure 2b). 
Valve-Related Morbidity: In the repair group there was one Warfarin-related gastro-
intestinal bleed due to erosive gastritis (in a patient in atrial fibrillation) versus 3 
Warfarin related bleeding episodes in the replacement group: Two abnormal uterine 
bleeds and one upper gastrointestinal bleed.  Infective endocarditis developed on one 
repaired valve, versus three in the replacement group. No prosthesis failures were 
encountered in the replacement group. Three patients in the replacement group 
developed a paravalvular leak. Two minor leaks were treated conservatively and one 
developed infective endocarditis and died. In the replacement group, only one valve 
thrombosed and underwent an early redo replacement.  













Actuarial freedom from all valve related events (deaths, re-operations, and morbidity) 
was 79.8±5.8% and 85.6±4.5% at 5 years and 69.8±8.4% and 69.2±10.7% at 10 years 
for the repairs and replacements respectively (N.S.) (Figure 3a). Actuarial freedom from 
all valve related events was 57.1±11.1% and 95.5±3.1% at 5 years (p=0.008) and 
41.6±12.4% and 95.5±3.1% at 10 years (p<0.001) for those mitral valve repairs with and 
without commissural fusion, respectively (p=0.0002 overall)(Figure 3b) 
 
Atrial fibrillation  
In the repair group, 20 (29%)(45% “Fused/ 20% “Non-Fused) were pre-operatively in 
permanent atrial fibrillation versus 27 (39%) in the replacement group.  In 13 of these 47 
cases a modified Maze procedure was performed with six (46%) remaining in sinus 
rhythm.  In each of the “Fused” and “Non-fused” commissural groups, two remained in 
sinus rhythm.  
New onset post-operative atrial fibrillation occurred in 6 patients (8.7%) in the repair 
group and 3 patients (4.3%) in the replacement group.  
 
Demographics, Population Migration and Follow-up 
Almost two thirds of the patients were of mixed race mirroring the demographics of 
South Africa’s Western Cape Province. Only one of 138 patients came from another 
province with 87% of patients living within 100km of the hospital. At the last follow-up 
(mean of 4.46±3.00 years after surgery) two thirds of patients had not changed their 
domicile. Most who had changed (25.4%) did so within the metropolitan area. Only 













In the rapidly urbanizing societies of threshold countries such as Brazil, India, China and 
South Africa rheumatic heart disease still accounts for a significant proportion of their 
350,000 annually performed cardiac operations. In contrast to previous eras, however, 
modern means of communication have thoroughly penetrated all levels of society, 
allowing even remote, indigent patient groups to be followed-up. The 100% follow-up 
rate in our present study gives testimony to these changed circumstances, opening the 
door to the optimization of therapies previously reserved for industrialized countries. By 
comparing disease progression after mitral valve repair with the adverse events associated 
with mitral valve replacement, we could demonstrate that: 
• the ten-year survival was not significantly different in replacements and repairs 
• while freedom from re-operation was significantly lower in the repair group, 
freedom from valve related events was identical in both groups 
• within the repair group, 10-year freedom from valve related events was 96% in 
those patients without fused commissures as opposed to 42% in those with fused 
commissures.  
In developing countries, perceived non-compliance with anticoagulation therapy had led 
to a strong advocacy of mitral valve repairs over replacements (2, 9). A significant 5-
year re-operation rate of 8% (10) to 23% (1) as a consequence of disease progression 
seemed acceptable in view of severe thromboembolic complications (11) and lethal 
thromboses of the prostheses (12). It was therefore an unexpected observation of our 
study that adverse events were less prevalent than anticipated in the replacement group 
with an identical survival rate as for mitral repairs. The reasons for this improved 
performance of mitral-valve replacements in a developing country may lie in an 
increased patient age at the time of surgery (associated with greater maturity and 
reliability), and better communication means between patients and health facilities. In 
our present study the mean patient age was 39 years. This trend towards rheumatic 
patients becoming symptomatic for surgery at a later stage in life was confirmed by 
Sliwa et al. At the same hospital where Antunes’ study was performed in 1986 the mean 
age of patients needing surgery in 2010 was 43 years (13) as opposed to 21 years (44% 












was still 25/100,000 patients/year it represents a true age-shift with advancing 
development rather than disease eradication - a trend reflected in a mean age at surgery 
of 49 years in South Korea (14) and 55 years in Taiwan (15). Notwithstanding, the large 
series of mitral valve repairs in rheumatic children in India and China (9) emphasizes the 
fact that the disease still affects many young patients.  
An additional explanation for our better outcomes may be that bi-leaflet prostheses had a 
higher impact in developing countries than in industrialized ones. A previous series from 
South Africa with tilting disc valves showed a 75% freedom from valve related mortality 
(11)  at 5 years, compared to 90% in our present study. 
The most significant outcome of our study, however, was the dramatic difference in 
freedom from valve related events of mitral valve repairs in those patients without 
commissural fusion versus those with fused commissures.  As much as previous studies 
had concluded that repairs in mixed mitral valve disease perform worse than in pure 
regurgitation (1, 2, 9) fused commissures are also a hallmark of pure mitral stenosis 
where commissurotomy leads to excellent long-term results. Whether an incompetence-
component in stenotic valves is a reflection of a more aggressive constrictive response of 
the fibrotic tissue remains speculative. It is, however, conceivable that additional 
anterior leaflet augmentation most recently advocated for the treatment of mixed mitral 
valve disease in order to counteract transversal leaflet traction (16-18) would have 
addressed this constriction and preempted the recurrence of incompetence. The fact that 
the predominant failure mode of valves that had commissural fusion in our study was 
incompetence rather than stenosis supports this explanation as does Acar’s report of a 
significantly lower re-operation rate in mixed mitral valve disease if anterior leaflet 
augmentation was employed (16). In the absence of anterior augmentation in past 
rheumatic repairs, our study identified commissural fusion as the one component of 
stenotic mitral valve disease that strongly suggests measures going beyond conventional 
repair strategies. Should long-term results with anterior leaflet augmentation in the 
subgroup with commissural fusion fall short of expectations, we have shown that 















This was a retrospective study of patients with all the well-known associated short-
comings, compared to a prospective study. The latter was not possible, predominantly 
due to problems with patient follow-up ten years ago when mobile phone penetration 
was low and there was more inter-provincial migration of patients. Reliance on mainly 
telephonic assessment at varying time points represents another weakness.  
Echocardiographic follow-up at predetermined time points would have been desirable 
but not implementable in the given population. As no strategy was implemented for late 
cardioversion of patients in atrial fibrillation, a less aggressive approach to Maze 
procedures was adopted. Anterior leaflet augmentations only became a reported 
modality in the latter half of the study but may have benefited the worst performing 
patients. 
Conclusions 
The long-term results for mitral valve replacement in an indigent, rheumatic heart 
disease population of a developing country in a modern era are distinctly better than 
generally perceived. Conventional mitral valve repair in rheumatic patients is an 
excellent, durable procedure if restricted to patients that do not have commissural fusion.  
Adding anterior leaflet augmentation in those valves showing commissural fusion and a 
Maze procedure in chronic atrial fibrillation may yet create a rheumatic patient 














Figure 1: Actuarial curves (Kaplan Meier) comparing overall survival (a) and survival 
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Figure 2: Actuarial freedom from re-operation (Kaplan Meier) comparing mitral valve 
replacement with all mitral valve repair patients (a) and between the subgroups of mitral 
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Figure 3:  Actuarial freedom from valve related events (Kaplan Meier) between mitral 
valve replacement and repair (a) and between repairs in mitral valves that had 
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Number of patients 69 69  





Female:Male ratio 54:15 58:11 0.5143 
Valve lesions (%)    
Pure stenosis  3  7  0.325 
Regurgitation  39  13  0.0001 
Stenosis and Regurgitation  27  49  0.0003 
Left atrial size (cm) 5.2±0.97 5.3±0.85 0.5206 
Pre-operative atrial fibrillation 29% 39% 0.2811 
Requiring additional tricuspid annuloplasty 5.7% 13% 0.2431 


















Operative Repair Data  No. Of Patients 
Intra-Operative Findings (%)  
Anterior Prolapse 52%(19) 
Anterior Restriction 18%(13) 
Posterior Prolapse 16%(11) 
Posterior Restriction 48%(33) 
Chordal Rupture 39%(27) 
Chordal Restriction 41%(28) 
Chordal Elongation 23%(16) 
Commissural Fusion 35%(24) 
No Commissural Fusion 65%(45) 
Annular Calcification 13%(20) 
Annular Dilatation 90%(19) 
Mitral Valve Repair Procedures  
Annuloplasty 90%(19) 
Medtronic CG-Future Band 68%(47) 
Carpentier-Edwards Physio Ring 13%(20) 
Carpentier Edwards Classic Ring 7.2%(20) 
Duran 1.4%(20) 
Commissurotomy 35%(24) 
Papillary muscle splitting 1.4%(20) 
Leaflet Cleft closures 10%(7) 
Chordal shortening 8.7%(6) 
Artificial chordae 49%(34) 
Leaflet Resection 11.6%(20) 
Leaflet Augmentation 19% (13) 





















Reason for late Death   % (events per 100 patient-years) 
 Repair Replacement 
Valve-Related   
Valve Thrombosis - 2 
Stroke  1 1 
Paravalvular Leak 0 1 
Post Redo MVR sudden cardiac arrest 1 0 
‘Sudden cardiac arrest’ 0 1 
Congestive Cardiac Failure 1 0 
Community Acquired Pneumonia 1 0 
HIV 0 2 
Cancer     2 * 0 
Murder 0 1 
Total 6 8 























Mean follow-up period (years) 4.53±2.98 4.39±3.04 0.785 
30 day mortality 0% 1.5% (20) 1.000 
Late Mortality 8.7% (6) 13% (20) 0.770 
Re-Operation Rate 14.5% (10) 1.5%(20) 0.009 
Mean time to re-operation (days) 954±890  46 (1 patient) - 
New onset atrial fibrillation 6 (8.7%) 3 (4.3%) 0.493 
Valve related events:    
     Post-op mitral valve endocarditis 1 (1.4%) 3 (4.3%) 0.619 
     Warfarin related bleed 1 (1.4%) 3 (4.3%) 0.619 
     Paravalvular leak - 3 (4.3%) - 
     Thrombosed valve (re-operated) - 1 (1.4%) - 
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Annexure D:  Journal of Heart Valve Disease Author Guidelines. 
 
Instruction to Authors 
Editorial policy 
The Journal of Heart Valve Disease publishes peer-reviewed scientific communications pertaining to heart 
valves and heart valve disease, including but not limited to all issues related to the scientific activity of 
The Society for Heart Valve Disease. These encompass all relevant clinical, surgical and laboratory 
specialties, multicenter trials, morphology, physiology, molecular biology, pathology as well as design, 
materials, test data and performances of replacement devices, relevant instruments and equipment. The 
scope of articles includes original publications, editorials, current and collective reviews, technical know-
how papers both in surgery and cardiology, case reports, correspondence and book reviews.  
Submission of a manuscript to the Journal implies the authors’ assertion that (a) it is original, (b) has not 
been published before and (c) is not under consideration, or under publication elsewhere. Prior publication 
of an abstract of 400 words or less does not prejudice the originality of a manuscript. 
Address  
Manuscripts and all editorial correspondence should be sent electronically to: 
rwemery@healtheast.org 
 
Review policy  
A manuscript will be evaluated not only with respect to its scientific competence and accuracy but also to 
its relative importance in the field of heart valve and heart valve disease and for its probable interest to our 
readership.  Each manuscript will be reviewed by the Editor and/or Associate Editor and at least 2-3 
additional outside reviewers.  Invited reviewers will evaluate each manuscript based on the following 
criteria: 
Originality 
The importance of the research question as it pertains to heart valves and heart valve disease; 
Scientific integrity 
Analytical methods appropriate for data presented; 
Data presented in a clear concise method; 
Tables, figures, illustrations and references are appropriate for the topic; 
Appropriate statistical methods applied and determination if statistical review should be considered; 
Manuscript format and content 
Are structure, content, grammatical, length and writing style consistent with guidelines; 
Is the discussion section relevant; 
Is the conclusion section reasonable and support the discussion. 
Acknowledgement of manuscript receipt 
The corresponding author will receive an acknowledgement by e-mail and an assigned unique tracking 
number. Any and all communication with the Editor regarding the status of a manuscript will be provided 
only to authors who identify the manuscript number.  When corresponding with the editorial office 
manuscripts must be referenced using the assigned number. 
Manuscript acceptance, revision and re-review  
The corresponding author will be notified by e-mail about the acceptance of a manuscript. If it accepted 
only conditionally pending revision, the corresponding author will receive all reviewer comments together 
with the editor’s recommendations. Revised manuscripts must be submitted in three parts: 1) a cover letter 
that provides a point-by-point response to reviewers’ comments; 2) the revised manuscript containing the 
deletions noted strikethrough and additions in bold; 3) the unmarked revised manuscript.  Revised 
manuscripts received after 3 months from the ‘Request to Revise” receipt date may be required to 
resubmit as a new manuscript and will be subject to the entire submission review process. 
Manuscripts that have been either undergone substantial revision or contain techniques/technology of 
controversial topics or articles discussing complex issues are subject to re-review at the discretion of the 
Editor.   
Copyright       












Publishers Ltd., and the copyright transfer document, which will be sent with the page proofs, should be 
signed by all authors of the article. 
Medical ethics  
Human studies.  Manuscripts reporting on human studies must adhere to the principles of the Helsinki 
Declaration (http://www.wma.net/e/policy/b3.htm).  Reports describing data obtained from research 
conducted in human participants must contain a statement in the Methods section indicating approval by 
the Institutional Review Board. If patients are identifiable from illustrations, photographs, study data or 
figures, release forms giving permission for publication must be submitted with the manuscript. 
Animal experiments. Manuscripts reporting experiments on living animals should adhere to the principles 
provided in the Guide for Care and Use of Laboratory Animals (www.nap.edu/catalog/5140.html) 
.  Manuscripts should also include in the Methods section a statement by the authors that the relevant 
regulations of the country where the experiments were carried out were fully observed.   
Conflict of interest 
All authors submitting any type of communication to be considered for publication in the Journal are 
expected to disclose any type of commercial association that might pose a conflict of interest in 
connection with that communication. All sources of funding of the work should be declared and 
acknowledged in a footnote. If the corporate or institutional affiliation of an author might constitute a 
conflict of interest, this fact should be communicated with the Editor in writing when the manuscript is 
submitted.  
Scientific contribution  
The maximum number of authors is eight, except in the case of multicenter studies. If there are more than 
three authors, each author will be required to state the type of scientific participation in the work. This can 
be (a) conception or design of protocol, collection, assessment or interpretation of data, (b) drafting the 
manuscript or revising its contents and (c) approval of the final v rsion to be sent for publication. 
Language  
The language of the Journal is the American version of medical/technical English. 
Checklist for manuscript preparation 
GENERAL  
• All manuscripts must be submitted electronically to: rwemery@healtheast.org, with a formal 
letter of submission. Hard copy submission is not necessary anymore.   
• Type the manuscript double spaced throughout, including title page, abstract, text, references, 
tables, figure legends.  
• Arrange the manuscript pages as follows: Cover letter, title page abstract, text, 
acknowledgements if applicable, references, tables, figure legends.  Each figure should be 
attached as a separate JPEG or TIFF file with an original resolution of 300 dpi. 
• Number all pages consecutively with arabic numbers, beginning with title page, ending with the 
(last) page of figure legends. 
LENGTH  
• The length of an original article should not exceed 4,500 words to include figure legends, tables 
and references. The combined total number of illustrations, tables and/or figures should not 
exceed eight and the number of references should not exceed 40. 
• Case reports should not exceed 1500 words, two figures or tables and eight references.  
• Authors of review articles should consult the editor.  
• Brief communications that contain substantive information concerning new, innovative or 
evolving technologies of clinical and/or scientific data pertaining to heart valves or heart valve 
disease are encouraged. They should not exceed 1000 words,  two tables or figures and no more 
than five references. 
• Readers are encouraged to submit Letters to the Editor on articles published in the 
Journal.  Submitted commentary letters will be provided to the original author and author replies 
will be published along with the commentary.  If the original author does not respond, a notation 
indicating.  “Response Declined” will be published.  Letters to the Editor should not exceed 750 
words, 1 table or figure and 5 references. 
TITLE PAGE 
• Keep the title as short as possible, not exceeding 12 words. Provide a short title not exceeding 












• Give three to five keywords for cross-indexing.  
• Give first names, middle initial(s) and last names of all authors with the respective highest 
academic qualification. Give the full name and location of not more than four institutional 
affiliation(s).  
• Give the name, full postal address, telephone and fax numbers, and e-mail address of the author 
to whom all correspondence, including page proofs and requests for reprints should be sent 
(corresponding author).  
• If the paper has been or is to be presented at a meeting of a scientific organization, give the name, 
venue and date of that meeting at the bottom of the title page.  
ABSTRACT 
Keep the length between 250 - 300 words for original publication and review articles, 150 - 200 words for 
case reports and other short communications. Organize the abstract in four major parts: 
• Background and aim of the study  




• Use the American version of medical/technical English, including spelling. Do not use 
abbreviations or acronyms, except for measurements. For the latter, follow the recommendations 
in “Uniform Requirements for Manuscripts Submitted to Biomedical Journals, 2nd Edition”, 
published in Ann Intern Med 1982;96:766-71 and Br Med J 1982;284:1766-70.  
• Mention every reference, figure (Fig.) and table (Table) in the text and number them 
consecutively as they first appear.  
REFERENCES 
• Mark all references with arabi numbers in brackets on the line. Personal communication, 
manuscript in preparation or sent for publication cannot be quoted as reference; they should be 
mentioned within parentheses in the text. Manuscript accepted for publication by a journal can be 
used as reference, stating the name of the journal and specifying “in press”.  
• The references should be numbered sequentially in the text and listed, on separate sheets, at the 
end of the text in that order. Reference format should conform to that known as the “Vancouver” 
style (http://www.library.uq.edu.au/training/citation/vancouv.pdf ) for biomedical journals. 
Journal abbreviations should conform to the style used in the Index Medicus. The page numbers 
should be inclusive, providing the first and last pages of the reference. Do not use full stop after 
the last page number. Each reference should include:  
 
- For journals: authors’ names and initials, title of article, journal name, year of publication, 
volume number, and inclusive pages (list all authors when six or less, when seven or more, list 
only three and add et al.) e.g.:  
 
Josa M, Khuri SF, Braunwald NS, et al. Delayed sternal closure: an improved method of dealing 
with complications after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1986;90:593-598 
 
- For book chapters: authors’ names, chapter title, editors’ name, book title, edition, city, 
publisher, year of publication and pages, e.g.:  
 
Berger HJ, Zaret BL, Cohen LS. Cardiovascular nuclear medicine. In Goldberger E, ed. 
Textbook of Clinical Cardiology. 1st ed. St Louis: CV Mosby, 1982:326-345  
 
- For books: authors’ names, book title, edition, city, publisher, year of publication, e.g.:  
 
Acar J, Bodnar E (eds). Textbook of Acquired Heart Valve Disease, Volume I and II, 1st edition, 
















• All illustrations, graphics and figures should be in JPEG or TIFF format.  The original resolution 
of the illustrations should be a minimum of 300 dpi. Bear in mind that the illustrations will be 
reproduced as single column width (8.25 cm, 3.25 inches) or double column width (17.15 cm, 
6.75 inches). Intermediate width will be considered only exceptionally.  
• The Journal cannot commit itself to reproduce unlimited color illustrations. If color is not 
absolutely necessary in the Editors’ opinion, the authors will be asked to share the additional 
expenses by advancing a payment of $ 1,500.00 and $ 350.00 for the first and every subsequent 
color illustration on a page, respectively.  
• Suitable legends should be typewritten, double spaced, listed on a separate page and included at 
the end of the manuscript.  
TABLES 
Tables should be self-explanatory and should supplement, not duplicate, the text. They should be typed on 
individual pages separate from the text. Provide a brief title for each. Abbreviations used in tables should 
be defined at the bottom of the table.  
LETTER OF PERMISSION 
Supply permission from both the publisher and the author to reproduce any previously published 
illustration or table. This letter of permission should be submitted at the time the final revised manuscript 
is submitted. 
COPY EDITING 
The Editors reserve all rights to make editorial revisions to aid clarity and understanding without altering 
the meaning. 
  
 
 
